Breast Cancer Drug Won't Be Offered to 1,000 Patients in England [BNN Bloomberg (Canada)]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: BNN Bloomberg
The drug, Enhertu, is already used in the National Health Service to treat patients with high levels of a protein called HER2 in breast tumors. However, the National Institute for Health and Care Excellence said Tuesday that it did not recommend it for advanced HER2-low breast cancer — an advanced, late-stage form of the disease — in England and Wales. Scotland approved the drug in December and it's available in 13 other European countries. NICE, as the regulator is known, published its final draft guidance after commercial negotiations ended between NHS England and Daiichi Sankyo, which holds the marketing rights in the UK. “The cost the NHS was being asked to pay was too high in relation to the benefits it provides for it to be recommended for routine use in the NHS,” said Helen Knight, director of medicines evaluation at NICE. She said the decision was disappointing as the drug was a significant development, yet added there was uncertainty over cost-effectiveness and how m
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Support [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow [Yahoo! Finance]Yahoo! Finance
- ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 TrialBusiness Wire
- Germany's Scholz pledges support for pharmaceutical industry [Yahoo! Finance]Yahoo! Finance
- FDA Roundup: April 9, 2024 [Yahoo! Finance]Yahoo! Finance